HKI-357

DB13002InvestigationalSmall molecule

Hki 357 is under investigation in clinical trial NCT00550381 (Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects).

Mechanism: Pharmacologically active on Ubiquitin-conjugating enzyme E2 C
Curator reviewed
Formula / weight: C₃₁H₂₉ClFN₅O₃ · 574.05 g/mol (avg)
Code names: HKI-357

Resolves to

Compound

UNII39R3638KZ6CAS848133-17-5ChEMBLCHEMBL178654PubChem11238512

Structure

InChIKeyNERXPXBELDBEPZ-RMKNXTFCSA-NSMILESCCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)=C(C=NC2=C1)C#N

Targets

O00762UBE2C

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with HKI-357, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account